1069 results about "Saline" patented technology

The invention provides materials, devices and methods for marking biopsy sites for a limited time. The biopsy-marking materials are ultrasound-detectable bio-resorbable powders, with powder particles typically between about 20 microns and about 800 microns in maximum dimension, more preferably between about 300 microns and about 500 microns. The powders may be formed of polymeric materials containing cavities sized between about 10 microns and about 500 microns, and may also contain binding agents, anesthetic agents, hemostatic agents, and radiopaque markers. Devices for delivering the powders include tubes configured to contain the powders and to fit within a biopsy cannula, the powders being ejected by action of a syringe. Systems may include a tube containing powder, and a syringe containing sterile saline. The tube may be configured to fit within a biopsy cannula such as a Mammotome® or SenoCor 360™ cannula.

An apparatus that is able to detect the position of a catheter. The apparatus utilizes a catheter filled with electrically-conductive physiological saline and a connector for establishing an electrical connection between the saline of the catheter and an input of a controller. The controller includes at least one output connectable to a standard ECG lead connector, wherein the controller includes circuitry for generating a low impedance output signal. The controller provides an output which replicates the input a standard ECG patient lead connector is configured to receive. The apparatus provides a more convenient and cost effective solution for providing specialized ECG functions without having to replace a hospital's existing ECG beside monitoring equipment.

The invention discloses an absorbable haemostatic material of a modified starch and a preparation method thereof. The haemostatic material is etherified modified starch or a composition which is formed by one or two or more than two of the etherified modified starch, cross-linked and composite modified starch, with a molecular weight of 15,000 to 2,000,000, a grain diameter of 10-1000Mu m and a water absorbency of 1 time to 100 times. The modified starch absorbable haemostatic material has the advantages that: the haemostatic material with biocompatibility is directly applied to bloody surface of wound to stop bleeding immediately, obviously increase the water absorbency and the water absorbing speed and have more viscosity and viscidity, thereby simultaneously blocking up damaged tissues and blood vessels while stopping bleeding. The haemostatic material is easy to swell or dissolve in water and after stopping bleeding, normal saline is used for washing to eliminate the haemostatic material not participating in stopping bleeding, thus reducing residues in the body, being beneficial to wound healing, and avoiding pains caused by unclosing pledget and bandage. The haemostatic material has the physical and chemical properties of stability, difficult decomposition, long guarantee period, convenient storage, high pressure resistance, low pressure resistance, high temperature resistance, low temperature resistance and difficult change.

The invention discloses an oil-in-water emulsion free of surfactant. The emulsion comprises a metabolizable oil phase, a water phase and oil-water amphipathic solid particles dispersed in the water phase and having biocompatibility, wherein the oil phase comprises squalene or / and tocol; the water phase is any one or a combination of at least two of purified water, water for injection, aqueous liquid of glycerol, buffered saline liquid and clinically available infusion liquid; and the average grain diameter of the solid particles is at nanometer-to-micron grade. The emulsion can be used as a vaccine adjuvant or a medicine delivery or controlled release carrier; the properties of the emulsion can be controlled and regulated; the obtained emulsion is stable; the use of a surfactant is avoided; and harm to the human body and pollution on the environmental can be reduced.

An apparatus and method for blood oxygenation is provided, advantageously comprising an extracorporeal circuit for the preparation and delivery of hyperoxic or hyperbaric blood. In one embodiment, an apparatus for gas-supersaturating fluids, e.g., physiologic saline, includes a chamber having a first inlet to receive the fluid; a second inlet to receive a gas, e.g., oxygen, from a gas supply that maintains pressure within the chamber at a predetermined level, advantageously about 600 p.s.i.; and an outlet advantageously coupled to a capillary assembly. An atomizer nozzle coupled to the first inlet advantageously creates within the chamber fine droplets of fluid into which gas diffuses to create the gas-supersaturated fluid, which collects within the chamber below the atomizer nozzle for removal via the outlet. The removed gas-supersaturated fluid mixes with blood provided by a blood pump, the mixing occurring within a liquid-to-liquid oxygenation assembly including a pressurizable chamber having inlets for the gas-supersaturated fluid and blood, the inlets advantageously arranged to create a vortical or cyclonic fluid flow within the chamber to promote mixing. The mixed fluid exits the chamber via an outlet for delivery to a patient (e.g., sub-selective delivery) or other site via a catheter, infusion guidewire, or other interventional fluid delivery device, the mixed fluid advantageously comprising blood having increased oxygen levels, i.e., oxygenated blood. Alternately, the blood may be provided by the pump to a high pressure hollow fiber or other type membrane oxygenator within which oxygen, advantageously provided at a pressure greater than atmospheric, diffuses across the membrane(s) and into the blood to form oxygenated blood, again for delivery to a patient or other site. Advantageously, the oxygenated blood is delivered at a target pO2 greater than about 760 mm Hg and is delivered from the liquid-to-liquid oxygenation assembly or membrane oxygenator via a fluid conduit having an approximate pressure drop greater than the target pO2.

An injectable and moldable putty comprising biodegradable calcium-based compounds including calcium sulfate, hydroxyapatite, and tricalcium phosphate is invented. The putty hardens into a solid body when mixed with water, saline, serum, or other neutral aqueous solutions. The hardening time of the putty can be tailored in order to meet the specific requirements of various dental or orthopedic applications. The pH of the putty is neutral during and after mixing. The invented putty may be used as bone graft, bone implant, or implantable drug delivery device.

The present disclosure provides for an adjuvant composition that is suited for injectable as well as transdermal administration. The adjuvant composition generally comprises a lipophile, a polymer of acrylic or methacrylic acid, saline, cholesterol, a saponin, and sodium hydroxide. A vaccine composition is also provided for that generally includes the vaccine composition of the present disclosure and a DNA component. A method for vaccinating animals and humans utilizing the adjuvant composition of the present disclosure is also provided.

The invention relates to the technical field of organ transplantation, and particularly discloses perfusion preservation fluid for an isolated liver. The perfusion preservation fluid for the isolated liver comprises donor whole blood, albumin, antibiotics, insulin, heparin, compound amino acid, glucose, dexamethasone, sodium chloride, sodium bicarbonate, normal saline, ATP-MgCl2 and S-adenosyl methionione which are mixed according to proportion. The isolated liver is preserved in the perfusion preservation fluid for 50 hours, the damage to liver cells is less, no complication occurs, the requirements of organ transplantation can be met, the survival time of a graft can be prolonged, and the survival rate of the graft in a host is improved; the perfusion preservation fluid is low in production cost and has the practical application value.

A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.

Provided is a water-absorbing agent which maintains a certain degree of liquid permeability and water absorption speed while also reducing re-wet in a disposable diaper, without the use of costly raw materials or costly apparatuses. The water-absorbing agent of the present invention contains a polyacrylic acid salt-based water-absorbing resin as a main component and has physical properties falling within a specific range, the physical properties being saline flow conductivity (SFC), gap fluid retention property under pressure, and a proportion of particles having a particle diameter of not less than 150 μm and less than 710 μm.

An intraocular lens (IOL) injector for delivering an IOL into an eye of a patient includes an IOL load chamber and connected delivery tube, and a push rod for urging the IOL through the delivery tube and out of a distal tip thereof. The push rod is guided and biased against one side of the injector load chamber. The injector may include an inflatable pusher for urging the IOL through the delivery tube and out of a distal tip thereof. The inflatable pusher has a proximal end that may be open to an internal cavity of the injector, wherein a plunger movable in the injector cavity forces fluid such as air or saline into the pusher. A distal end of the pusher may be forked to capture a trailing end of the IOL, or may have a bulbous configuration to ensure the pusher does not pass the IOL.

An instrument for precisely cutting tissue to controlled dimensions (length, width, depth, and shape) is provided for the removal of tissue specimens from remote sites in the body of a patient, such as from the gastrointestinal tract, urinary tract, or vascular structures, or any tissue surface or soft tissue of the body. The instrument has a housing and a substantially flexible shaft extending from the housing to a distal end. The distal end of the instrument has an open cavity into which tissue is receivable. Suction can be communicated along the shaft to the distal end for distribution across the cavity utilizing a manifold having a grated tissue engaging surface with opening(s) for applying the suction, thereby pulling tissue adjacent to the distal end into the cavity against the tissue engaging surface of the manifold. One or more hollow needles are extendable from the housing through the shaft into the cavity to enable infusion of fluid, such as saline or a hemostatic agent, into the tissue. A blade in the distal end is extendable through the cavity over the manifold and across the opening to cut the tissue held by suction and stabilized by the needles in the cavity. The shape and depth of the tissue removed by the cuts is in accordance with the contour of the tissue engaging surface and the size and shape of the cavity at the distal end. The tissue so removed by the instrument may be for therapeutic intervention and / or represent a tissue specimen for biopsy suitable of diagnostic evaluation. The tissue edges in the patient's body left after cutting with this instrument readily avail themselves to apposition for enhanced healing.